- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03047629
Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation (RASMET)
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Phase 1 will enroll 10 patients to assess the safety, tolerability, and pharmacokinetics of single escalating doses over a 30-60 day period. The dose-escalation period will be preceded by a 2-week run in period and followed by a 2-week wash-out period.
Phase 2 follow the safe completion of Phase 1. It will enroll 40 patients and is composed of 4 periods of study: 1) a 2-week run-in period, 2) a 3-5 week escalating dose period to identify a prokinetic dose in the initial set of 10 patients, 3) a 1-week period of randomized dosing (placebo versus the previously identified pro-kinetic dose), and 4) a 2-week wash-out period. Pharmacodynamics will be assessed along with safety and tolerability. Relative outcomes will be compared within each patient and across groups for the randomized dosing period.
Frequency of bowel movements and other non-motor symptoms of Parkinson's Disease will be collected over the course of both phases.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Keck Hospital of University of Southern California
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- Rocky Mountain Movement Disorders Center, PC
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown Universtiy, Department of Neurology
-
-
Florida
-
Boca Raton, Florida, United States, 33486
- Parkinson's Disease And Movement Disorders Center of Boca Raton
-
Jacksonville, Florida, United States, 32209
- Neuroscience Research, University of Florida Jacksonville
-
Port Charlotte, Florida, United States, 33952
- MEDSOL Clinical Research
-
Saint Petersburg, Florida, United States, 33713
- Suncoast Neuroscience Associates, Inc
-
Sarasota, Florida, United States, 34239
- Sarasota Memory Hospital Clinical Research Ctr.
-
Tampa, Florida, United States, 33613
- USF Health Byrd Parkinson's Disease Movement Disorders Center of Excellence
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48334
- Quest Research Institute
-
-
New York
-
New York, New York, United States, 10029
- Movement Disorders Division, Mt. Sinai School of Medicine
-
-
Ohio
-
Cincinnati, Ohio, United States, 45212
- Riverhills Healthcare, Inc.
-
Cleveland, Ohio, United States, 44106
- Parkinson's & Movement Disorders Center, UH Cleveland Medical Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Health, Department of Neurology
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University, Department of Neurology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Parkinson's disease diagnosis confirmed by a neurologist specializing in movement disorders
- Insufficient criteria for a diagnosis of Irritable Bowel Syndrome
- Constipation for over 6 months, unresponsive to Milk of Magnesia, and requiring at least weekly treatment using an oral laxative, stool softener, bulking agent, and/or a suppository, and dissatisfaction with current treatment.
- Body Mass Index is 18-40 kg/m2
- At least 2 of the Rome IV functional constipation criteria are met
- Loose stools are rarely present without the use of laxatives
- Patient is willing and able to sign informed consent and comply with all study procedures
Patients must be able to read, understand, and accurately record data into the diary to guarantee full participation in the study
Females only:
- Must have negative serum or urine pregnancy tests and must not be lactating
- If of child-bearing age: Must agree to using a hormonal (i.e., oral, implantable, or injectable) and either single- or double-barrier method of birth control throughout the study period. A vasectomized partner will be allowed as one in conjunction with another single-barrier method.
- If unable to have children: Must have this documented in the case report form (i.e., ubal ligation, hysterectomy, or post-menopausal [defined as a minimum of one year since last menstrual period]). Post-menopausal status will be confirmed by follicle stimulating hormone in women less than 60 years of age.
Exclusion Criteria:
- Unable or unwilling to provide informed consent or to comply with study procedures
- Diagnosis of secondary constipation beyond that of PD
- Structural or metabolic diseases that affect the GI system
- Functional GI disorder
- Unable or unwilling to withdraw from taking the following medications 2 weeks prior to the dose-escalation period and throughout the study: Laxatives, opiates, sedatives, hypnotics, anti-histamines, protein pump inhibitors or any medications which may cause constipation
- History of recent major surgery (within 60 days of screening)
- Any clinically significant abnormalities on screening laboratories or physical examination as determined by the Investigator
- Neurological disorder other than PD
- On treatment with intra-jejunal dopamine
- Treatment with COMT inhibitors for fewer than 4 weeks (entacapone, tolcapone, Stalevo)
- Unable to maintain a stable diet regimen
- Patients with a cognitive impairment that preclude them from understanding the informed consent
- Patients placed under legal guardianship
- Acute GI illness within 48 hours of the baseline period
- History of major GI surgery (e.g. previous abdominal surgery, including cholecystectomy), except that patients with uncomplicated appendectomy are allowed
- ALT or AST > 1.5 X upper limit of normal (ULN) during screening
- Females who are pregnant or breastfeeding
- History of excessive alcohol use or substance abuse
- Patient or caregiver unable to administer daily oral dosing
- Participation in an investigational clinical study within the 6 months prior to dosing in the present study
- Any other reason, which in the opinion of the Investigator would confound proper interpretation of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ENT-01
ENT-01 at a to-be-determined dose taken by mouth every day upon awakening.
|
Daily dosing with ENT-01.
ENT-01 is an orally administered proprietary substance formulated as a small 25mg coated tablet.
Dosing will range from 25-200mg, and the dose will be taken upon awakening on an empty stomach with 8oz water simultaneous to dopamine.
|
Placebo Comparator: Placebo Comparator
Placebo to be taken by mouth every day upon awakening
|
Daily dosing with a placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events.
Time Frame: Through study completion, up to 11 weeks
|
Specific treatment related events of recurrent vomiting, recurrent diarrhea, abdominal pain, and hypotension will be assessed with respect to grade and frequency of occurrence.
|
Through study completion, up to 11 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Bowel Movements
Time Frame: Through study completion, up to 11 weeks
|
The frequency of spontaneous bowel movements will be assessed at each dose across the study population and compared to baseline measures.
|
Through study completion, up to 11 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Denise Barbut, MD FRCP, Enterin Inc.
- Principal Investigator: Steven Frucht, MD, NYU Langone Health
- Principal Investigator: Robert Hauser, MD MBA, University of South Florida
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ENT-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
AbbVieRecruitingParkinson's Disease (PD)Germany, Denmark, Spain
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Hubert FernandezRecruitingParkinson's Disease, IdiopathicUnited States
Clinical Trials on ENT-01
-
Enterin Inc.TerminatedParkinson Disease | ConstipationUnited States
-
Enterin Inc.CompletedParkinson Disease | ConstipationUnited States
-
Enterin Inc.WithdrawnParkinson Disease | DementiaUnited States
-
Enterin Inc.RecruitingObesity | Diabetes Mellitus, Type 2United States
-
Washington University School of MedicineCompleted
-
Hopital FochHôpital Raymond PoincaréCompletedCOVID-19 | Olfaction DisordersFrance
-
University of CalgaryRecruitingEustachian Tube Dysfunction | BarotitisCanada
-
Emory University3NT Medical Ltd.TerminatedSinus ProblemUnited States
-
University Hospital Center of MartiniqueRecruitingDysphagia | Swallowing DisorderFrance
-
Norwegian University of Science and TechnologyHelse Stavanger HF; St. Olavs Hospital; Sykehuset Innlandet HF; Alesund Hospital; Molde Hospital and other collaboratorsCompleted